EUVIMEDDescoperă EUVIMED
CrossrefCard informativ

Controlled Hypothermic Storage and Time‐Shifting in Lung Transplantation: A Single‐Center Study

Andrew Keogan, Theodore Lin, Mark Shacker, Lucia Chang, Lucas Wang, Rajat Walia, Ross M. Bremner, Jasmine Huang, Nathan Zwintscher, Michael A. Smith, Lara W. Schaheen

Clinical Transplantation · 2026-11 · 40 (11)

DOI: 10.1111/ctr.70684 ↗
RezumatDate bibliografice

Rezumat

ABSTRACT Purpose This study compared lung transplant outcomes between cases using controlled hypothermic storage (CHS) donor lung transport with ischemic times > 6 h and those using cold static storage (CSS) transport with ischemic times < 6 h. Methods We retrospectively reviewed lung transplantations performed at our center from September 15, 2014 to March 29, 2025, excluding ex vivo lung perfusion, single‐lung, redo, and multi‐organ cases. Perioperative outcomes were assessed using univariate, multivariable, survival, and propensity‐matched analyses. Results Among 770 recipients, 87 (11.3%) and 683 (88.7%) received lungs preserved using CHS and CSS, respectively. In the CHS group, ischemic times were significantly longer (median, 11.0 vs. 4.3 h, p < 0.001), and transport distances were greater (median, 750 vs. 219 nautical miles, p < 0.001). CHS was associated with higher rates of daytime transplantation (79% vs. 51%, p < 0.001) and delayed chest closure (22% vs. 13%, p = 0.023). Primary graft dysfunction grade 3 (PGD3) at 72 h was lower in the CHS group (13% vs. 26%, p = 0.019), and CHS was independently associated with a lower risk of PGD3 on multivariable analysis (aOR 0.38, 95% CI 0.17–0.83, p = 0.016). In a propensity‐matched analysis, PGD3 at 72 h was lower in the CHS group, but the difference did not reach statistical significance (12% vs. 26%, p = 0.059). Kaplan–Meier analysis demonstrated similar survival between groups ( p = 0.53). Conclusion CHS enables the safe extension of ischemic time beyond conventional limits, facilitating broader geographic access and a shift toward increased daytime transplantation. Short‐term outcomes were comparable to those of CSS, with a lower incidence of PDG3.

Cunoștințe potrivite muncii dumneavoastră.

De la începutul gratuit și cercetarea bibliografică personală până la Research Suite complet.

Vezi tarifele →

Sunt incluse toate textele integrale ale editorilor?

Nu. Referințele bibliografice, rezumatele și textele integrale sunt conținuturi diferite. Disponibilitatea unui text integral depinde de sursă, de Open Access și de licențele pe care le aveți deja. Un abonament EUVIMED nu înlocuiește drepturile suplimentare ale editorilor.

Vezi tarifele →